PARSIPPANY, N.J.--(BUSINESS WIRE)--Ferring Pharmaceuticals today announced the final 60-month follow-up data from the Phase 3 study of ADSTILADRIN ® (nadofaragene firadenovec-vncg) were presented at ...

Preliminary results of phase II trial of concomitant administration of intra-vesical reduced dose Bacillus Calmette- Guerin (BCG) and interferon a 2B (IFN) in the prevention of recurrence of ...

The FDA has approved nadofaragene firadenovec (Adstiladrin) as the first gene therapy for the treatment of high-risk bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer ...

Each year, more than 100 million newborns around the world receive vaccinations against Mycobacterium tuberculosis, or TB, which infects about one-quarter of the world's population. Facilities across ...

A second course of BCG in this population may achieve a response rate of up to 34%. Nonetheless, especially for high-grade disease, radical cystectomy should be offered as definitive therapy in BCG ...

Each year, more than 100 million newborns around the world receive vaccinations against Mycobacterium tuberculosis, or TB, which infects about one-quarter of the world’s population. Facilities across ...

A systematic review evaluated current and investigational intravesical and systemic therapies for NMIBC after BCG failure, including chemotherapy, immunotherapy, combination therapy, hyperthermia, and ...

Background and aims: Tuberculosis is one of the major health problems in the world. Interferon gamma release assay (IGRA) is a novel tool for Mycobacterium tuberculosis infection diagnosis. The aim of ...